Quantedge Capital Pte Ltd trimmed its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 20.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 267,755 shares of the specialty pharmaceutical company's stock after selling 70,445 shares during the quarter. Collegium Pharmaceutical accounts for about 2.8% of Quantedge Capital Pte Ltd's holdings, making the stock its 6th largest position. Quantedge Capital Pte Ltd owned about 0.83% of Collegium Pharmaceutical worth $7,671,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Nisa Investment Advisors LLC increased its stake in Collegium Pharmaceutical by 14.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock worth $71,000 after acquiring an additional 316 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Collegium Pharmaceutical by 1.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,221 shares of the specialty pharmaceutical company's stock worth $522,000 after acquiring an additional 339 shares during the last quarter. AlphaQuest LLC increased its stake in Collegium Pharmaceutical by 3.0% in the 4th quarter. AlphaQuest LLC now owns 12,780 shares of the specialty pharmaceutical company's stock worth $366,000 after acquiring an additional 374 shares during the last quarter. Foundry Partners LLC increased its stake in Collegium Pharmaceutical by 2.4% in the 4th quarter. Foundry Partners LLC now owns 16,162 shares of the specialty pharmaceutical company's stock worth $463,000 after acquiring an additional 381 shares during the last quarter. Finally, Gallacher Capital Management LLC increased its stake in Collegium Pharmaceutical by 3.3% in the 4th quarter. Gallacher Capital Management LLC now owns 14,571 shares of the specialty pharmaceutical company's stock worth $417,000 after acquiring an additional 470 shares during the last quarter.
Insider Activity at Collegium Pharmaceutical
In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 40,000 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total value of $1,123,200.00. Following the completion of the sale, the executive vice president now owns 154,204 shares in the company, valued at approximately $4,330,048.32. This trade represents a 20.60% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Colleen Tupper sold 10,445 shares of the stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $30.01, for a total value of $313,454.45. Following the completion of the sale, the chief financial officer now owns 165,246 shares of the company's stock, valued at approximately $4,959,032.46. This trade represents a 5.95% decrease in their position. The disclosure for this sale can be found here. Insiders sold 81,693 shares of company stock worth $2,334,994 in the last ninety days. 2.51% of the stock is owned by company insiders.
Collegium Pharmaceutical Trading Up 3.0%
COLL stock traded up $0.89 during trading on Friday, hitting $30.23. 430,854 shares of the company traded hands, compared to its average volume of 429,513. The firm has a market capitalization of $971.35 million, a PE ratio of 13.03 and a beta of 0.63. Collegium Pharmaceutical, Inc. has a 1 year low of $23.23 and a 1 year high of $42.29. The company has a 50-day moving average of $28.12 and a 200-day moving average of $29.85. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97.
Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share for the quarter, missing the consensus estimate of $1.50 by ($0.01). The company had revenue of $177.76 million for the quarter, compared to analysts' expectations of $174.96 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The company's revenue was up 22.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.45 earnings per share. Analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several brokerages have recently commented on COLL. Needham & Company LLC reiterated a "buy" rating and set a $46.00 price objective on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. StockNews.com lowered Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Saturday, April 19th. Piper Sandler reiterated a "neutral" rating and set a $37.00 price objective (up from $36.00) on shares of Collegium Pharmaceutical in a research report on Friday, May 9th. Finally, HC Wainwright reiterated a "buy" rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $43.80.
View Our Latest Stock Report on Collegium Pharmaceutical
Collegium Pharmaceutical Profile
(
Free Report)
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
See Also
Before you consider Collegium Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Collegium Pharmaceutical wasn't on the list.
While Collegium Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
